Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000002005 | SCV001199839 | pathogenic | 3-methylcrotonyl-CoA carboxylase 2 deficiency | 2023-10-08 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 16 of the MCCC2 gene. While this variant is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product. This variant is present in population databases (rs730880265, gnomAD 0.003%). Disruption of this splice site has been observed in individual(s) with 3-methylcrotonyl-CoA carboxylase deficiency (PMID: 16010683). ClinVar contains an entry for this variant (Variation ID: 1928). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts a region of the MCCC2 protein in which other variant(s) (p.Gly559Asp) have been determined to be pathogenic (PMID: 27033733; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000002005 | SCV000022163 | pathogenic | 3-methylcrotonyl-CoA carboxylase 2 deficiency | 2005-01-01 | no assertion criteria provided | literature only |